Fig. 4: Efficacy of lestaurtinib in ex vivo PDX models. | npj Precision Oncology

Fig. 4: Efficacy of lestaurtinib in ex vivo PDX models.

From: Lestaurtinib’s antineoplastic activity converges on JAK/STAT signaling to inhibit treatment naïve and therapy resistant forms ovarian cancer

Fig. 4

a Depiction of ovarian cancer PDX processing for rapid evaluation of drug efficacy in ex vivo cultures. Created with BioRender.com. b Viability of PDX models following 3 days of lestaurtinib treatment as assessed via 3D CellTiter-Glo. N = 3–6. Volcano plots depicting differentially expressed genes in (c) PH039R vs PH039S, d PH077R vs PH077S, and e lestaurtinib sensitive (PH039R, PH730, PH580) vs lestaurtinib resistant (PH039S, PH077S, PH077R, PH354) PDXs as determined by RNAseq, where blue indicates significantly downregulated genes and red indicates significantly upregulated genes ( | fold change | ≥ 1.5, p < 0.05 and FDR < 0.1). The number of significantly regulated genes are shown. f–k Ingenuity Pathway Analysis and upstream regulator assessment of differentially expressed genes between the indicated PDX models. Pathways and up-stream regulators with p < 0.05 and |z-score | > 2 were considered as significant. Abbreviations: Lest lestaurtinib, Sen sensitive, Res resistant. Graphs depict mean ± standard error. ANOVA p-values: *<0.0332,**<0.0021,***<0.0002,****<0.0001.

Back to article page